1172 related articles for article (PubMed ID: 21466967)
1. [Allogeneic hematopoietic stem cell transplantations].
Michallet M
Transfus Clin Biol; 2011 Apr; 18(2):235-45. PubMed ID: 21466967
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
[TBL] [Abstract][Full Text] [Related]
4. [The methods used to collect hematopoietic stem cells].
Hequet O
Transfus Clin Biol; 2011 Apr; 18(2):230-4. PubMed ID: 21397542
[TBL] [Abstract][Full Text] [Related]
5. Adoptive allogeneic immunotherapy--history and future perspectives.
Schleuning M
Transfus Sci; 2000 Oct; 23(2):133-50. PubMed ID: 11035275
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy with allogeneic haematopoietic stem cell transplantation: current status and perspectives].
Mohty M; Faucher C; Blaise D
Rev Med Interne; 2005 Jan; 26(1):33-40. PubMed ID: 15639324
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
8. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of murine leukemia following non-myeloablative conditioning with naïve or G-CSF mobilized blood or bone marrow stem cells.
Weiss L; Or R; Slavin S; Naparstek E; Reich S; Abdul-Hai A
Cancer Immunol Immunother; 2004 Apr; 53(4):358-62. PubMed ID: 14605765
[TBL] [Abstract][Full Text] [Related]
10. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients.
Bay JO; Fleury J; Choufi B; Tournilhac O; Vincent C; Bailly C; Dauplat J; Viens P; Faucher C; Blaise D
Bone Marrow Transplant; 2002 Jul; 30(2):95-102. PubMed ID: 12132048
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
14. Combining Mobilizing Agents with Busulfan to Reduce Chemotherapy-Based Conditioning for Hematopoietic Stem Cell Transplantation.
Garcia-Perez L; van Roon L; Schilham MW; Lankester AC; Pike-Overzet K; Staal FJT
Cells; 2021 Apr; 10(5):. PubMed ID: 33946560
[TBL] [Abstract][Full Text] [Related]
15. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
17. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
18. Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.
Slavin S; Nagler A; Aker M; Shapira MY; Cividalli G; Or R
Rev Clin Exp Hematol; 2001 Jun; 5(2):135-46. PubMed ID: 11486652
[TBL] [Abstract][Full Text] [Related]
19. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.
Champlin R; Khouri I; Anderlini P; Gajewski J; Kornblau S; Molldrem J; Shimoni A; Ueno N; Giralt S
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S13-22. PubMed ID: 11436116
[TBL] [Abstract][Full Text] [Related]
20. Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets.
Melve GK; Ersvaer E; Eide GE; Kristoffersen EK; Bruserud Ø
Front Immunol; 2018; 9():845. PubMed ID: 29770133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
